Compare MEI & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEI | VALN |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.1M | 653.3M |
| IPO Year | 1994 | 2021 |
| Metric | MEI | VALN |
|---|---|---|
| Price | $13.58 | $6.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $9.00 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 705.8K | 27.6K |
| Earning Date | 03-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.61% | N/A |
| EPS Growth | ★ 42.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $908,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.24 | N/A |
| 52 Week Low | $4.88 | $4.75 |
| 52 Week High | $20.38 | $12.23 |
| Indicator | MEI | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 42.51 | 54.11 |
| Support Level | $12.56 | $6.29 |
| Resistance Level | $17.82 | $6.60 |
| Average True Range (ATR) | 1.04 | 0.21 |
| MACD | -0.20 | -0.07 |
| Stochastic Oscillator | 10.95 | 23.72 |
Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, with the majority of revenue from Europe, the Middle East & Africa (EMEA).
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.